Adamis Pharmaceuticals Corporation (ADMP): Price and Financial Metrics

Adamis Pharmaceuticals Corporation (ADMP): $0.78

0.01 (+0.86%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

ADMP Price/Volume Stats

Current price $0.78 52-week high $26.18
Prev. close $0.77 52-week low $0.75
Day low $0.75 Volume 119,800
Day high $0.79 Avg. volume 811,695
50-day MA $1.54 Dividend yield N/A
200-day MA $7.60 Market Cap 7.25M

ADMP Stock Price Chart Interactive Chart >


Adamis Pharmaceuticals Corporation (ADMP) Company Bio


Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, engages in developing and commercializing products in the therapeutic areas of allergy and respiratory disease. The company is based in San Diego, California.


ADMP Latest News Stream


Event/Time News Detail
Loading, please wait...

ADMP Latest Social Stream


Loading social stream, please wait...

View Full ADMP Social Stream

Latest ADMP News From Around the Web

Below are the latest news stories about ADAMIS PHARMACEUTICALS CORP that investors may wish to consider to help them evaluate ADMP as an investment opportunity.

Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus

Company to begin trading under new ticker symbol “DMK” on September 8, 2023SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the company changed its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing small molecules for the treatment of substance use disorders. In conjunction with the name change, the company’s common stock is expected

Yahoo | September 7, 2023

Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. Q2 2023 Corporate Highlights In May, the Company closed the merger with DMK Pharmaceuticals Corporation (DMK), a private, clinical-stage biotechnology company at the forefront of endorphin-inspired drug design focused on de

Yahoo | August 21, 2023

Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering

SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of common stock. Each unit was sold at a public offering price of $1.35. The common warrants are immediately exercisable at a price of $1.35 per share and

Yahoo | August 4, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off the day with a breakdown of all the biggest pre-market stock movers worth reading about on Thursday morning!

William White on InvestorPlace | August 3, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time for another breakdown of the biggest pre-market stock movers as we check out all of the latest news for Wednesday!

William White on InvestorPlace | August 2, 2023

Read More 'ADMP' Stories Here

ADMP Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year -98.38%
5-year -99.26%
YTD N/A
2023 0.00%
2022 -72.02%
2021 24.72%
2020 -30.74%
2019 -68.87%

Continue Researching ADMP

Here are a few links from around the web to help you further your research on Adamis Pharmaceuticals Corp's stock as an investment opportunity:

Adamis Pharmaceuticals Corp (ADMP) Stock Price | Nasdaq
Adamis Pharmaceuticals Corp (ADMP) Stock Quote, History and News - Yahoo Finance
Adamis Pharmaceuticals Corp (ADMP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!